Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
ATHE Stock Chart & Stats
$3.55
-$0.16(-4.23%)
At close: 4:00 PM EST
$3.55
-$0.16(-4.23%)
Day’s Range― - ―
52-Week Range$2.66 - $7.00
Previous CloseN/A
Volume131.33K
Average Volume (3M)13.05K
Market Cap
$69.12M
Enterprise Value$48.84M
Total Cash (Recent Filing)$49.15M
Total Debt (Recent Filing)$98.35K
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding18,125,694
10 Day Avg. Volume16,981
30 Day Avg. Volume13,055
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue12.74
Enterprise Value/Gross Profit13.16
Enterprise Value/Ebitda-2.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$3.88M
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsConsistently >90% gross margins indicate durable cost advantages or premium pricing in core activities. High gross margins provide structural leeway to fund R&D and absorb SG&A as revenue scales, supporting long-term program advancement even before profitability is achieved.
Notable Revenue Growth (46% YoY)A 46% revenue increase demonstrates meaningful top-line traction for a clinical-stage biotech. Sustained revenue growth can help spread fixed R&D costs, improve operational leverage over months, and validate commercial/partnering potential independent of short-term market swings.
Low Leverage / Conservative Capital StructureMinimal debt reduces refinancing and interest-rate risk while clinical programs progress. A conservative capital structure preserves strategic flexibility to raise non-debt financing or negotiate partnerships, supporting the multi-month funding runway needed for development milestones.
Bears Say
Persistent UnprofitabilityOngoing negative EBIT and net margins mean the business does not generate operating profits from current activities. Over a multi-month horizon this necessitates external funding or partnerships to continue programs, increasing dilution or strategic dependency absent near-term commercialization.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow reflect structural cash burn to support trials and operations. With FCF roughly aligned to negative net income, the company faces sustained liquidity pressures that can constrain program timing and require financing actions within months.
Negative Return On EquityA negative ROE signals shareholders' capital is not producing returns and highlights inefficiency in converting invested equity into value. Persistently negative ROE can deter long-term funding sources and raises the likelihood of dilutive raises or strategic exits to sustain development.
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $2.66 and its highest was $7.00 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $69.12M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 325 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 25, 2026. The company reported -$0.383 earnings per share for the quarter, missing the consensus estimate of -$0.231 by -$0.152.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Overvalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 18,125,694 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.383 in its last earnings report, missing expectations of -$0.231. Following the earnings report the stock price went up 2.945%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.18%
12-Months-Change
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.27% Other Institutional Investors
98.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---